This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Cetrotide — Description, Dosage, Side Effects | PillsCard
Rx
Cetrotide
0,25 mg (0,25 mg/ml), Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
INN: Cetrorelixum
Available in:
🇨🇿🇩🇪🇬🇧🇫🇷🇵🇱🇸🇰🇹🇷🇺🇦
Form
Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
Dosage
0,25 mg (0,25 mg/ml)
Route
podskórna
Storage
—
About This Product
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
Merck Europe B.V. (Niemcy)
Composition
Cetrorelixum 0,25 mg
ATC Code
H01CC02
Source
URPL
Pharmacotherapeutic group: anti-gonadotropin-releasing hormones, ATC code: H01CC02.
Mechanism of action
Cetrorelix is a luteinising hormone releasing hormone (LHRH) antagonist. LHRH binds to membrane receptors on pituitary cells. Cetrorelix competes with the binding of endogenous LHRH to these receptors. Due to this mode of action, cetrorelix controls the secretion of gonadotropins (LH and FSH).
Cetrorelix dose-dependently inhibits the secretion of LH and FSH from the pituitary gland. The onset of suppression is virtually immediate and is maintained by continuous treatment, without initial stimulatory effect.
Clinical efficacy and safety
In females, cetrorelix delays the LH surge and consequently ovulation. In women undergoing ovarian stimulation the duration of action of cetrorelix is dose dependent. Repeated injections of Cetrotide 0.25 mg per vial (administered dose of 0.21 mg cetrorelix), every 24 hours will maintain the effect of cetrorelix (see section 4.2).
In animals as well as in humans, the antagonistic hormonal effects of cetrorelix were fully reversible after termination of treatment.
⚠️ Warnings
This medicinal product must be allowed to reach room temperature prior to injection. It should be removed from the refrigerator approximately 30 minutes before use.
Cetrotide should only be reconstituted with the solvent provided, using a gentle, swirling motion. Vigorous shaking with bubble formation should be avoided.
The reconstituted solution is without particles and clear. Do not use if the solution contains particles or if the solution is not clear.
The entire contents of the vial should be withdrawn to ensure a delivery to the patient of a dose of 0.21 mg cetrorelix (see section 4.2).
The solution should be used immediately after reconstitution.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
